• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

需要进行重复的 mRNA 疫苗接种,以在缺乏 CXCL13 的情况下提高广谱抗 SARS-CoV-2 抗体的质量。

Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.

机构信息

INSERM-U1124, Université Paris Cité, Paris, France.

Structural and Molecular Analysis Platform, BioMedTech Facilities INSERM US36-CNRS UMS2009, Université Paris Cité, Paris, France.

出版信息

Sci Adv. 2023 Aug 4;9(31):eadg2122. doi: 10.1126/sciadv.adg2122.

DOI:10.1126/sciadv.adg2122
PMID:37540749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10403221/
Abstract

Since the initial spread of severe acute respiratory syndrome coronavirus 2 infection, several viral variants have emerged and represent a major challenge for immune control, particularly in the context of vaccination. We evaluated the quantity, quality, and persistence of immunoglobulin G (IgG) and IgA in individuals who received two or three doses of messenger RNA (mRNA) vaccines, compared with previously infected vaccinated individuals. We show that three doses of mRNA vaccine were required to match the humoral responses of preinfected vaccinees. Given the importance of antibody-dependent cell-mediated immunity against viral infections, we also measured the capacity of IgG to recognize spike variants expressed on the cell surface and found that cross-reactivity was also strongly improved by repeated vaccination. Last, we report low levels of CXCL13, a surrogate marker of germinal center activation and formation, in vaccinees both after two and three doses compared with preinfected individuals, providing a potential explanation for the short duration and low quality of Ig induced.

摘要

自严重急性呼吸综合征冠状病毒 2 感染最初传播以来,已经出现了几种病毒变体,这对免疫控制构成了重大挑战,特别是在接种疫苗的情况下。我们评估了接受两剂或三剂信使 RNA(mRNA)疫苗的个体中免疫球蛋白 G(IgG)和 IgA 的数量、质量和持久性,与先前感染过疫苗的个体进行了比较。我们表明,需要三剂 mRNA 疫苗才能与预先感染的疫苗接种者的体液反应相匹配。鉴于抗体依赖性细胞介导的免疫对病毒感染的重要性,我们还测量了 IgG 识别细胞表面表达的刺突变异体的能力,发现重复接种也大大增强了交叉反应性。最后,我们报告说,与预先感染的个体相比,接受两剂和三剂疫苗后的疫苗接种者的 CXCL13(生发中心激活和形成的替代标志物)水平较低,这为 Ig 诱导的持续时间短和质量低提供了一个潜在的解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/39fe9d248982/sciadv.adg2122-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/23d34455ade4/sciadv.adg2122-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/b7a2e7c3ca66/sciadv.adg2122-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/0fa4c80f583e/sciadv.adg2122-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/f9999cfe62a8/sciadv.adg2122-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/b7c35e187eb3/sciadv.adg2122-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/73f80c4388ca/sciadv.adg2122-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/39fe9d248982/sciadv.adg2122-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/23d34455ade4/sciadv.adg2122-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/b7a2e7c3ca66/sciadv.adg2122-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/0fa4c80f583e/sciadv.adg2122-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/f9999cfe62a8/sciadv.adg2122-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/b7c35e187eb3/sciadv.adg2122-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/73f80c4388ca/sciadv.adg2122-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eaf7/10403221/39fe9d248982/sciadv.adg2122-f7.jpg

相似文献

1
Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti-SARS-CoV-2 antibodies in the absence of CXCL13.需要进行重复的 mRNA 疫苗接种,以在缺乏 CXCL13 的情况下提高广谱抗 SARS-CoV-2 抗体的质量。
Sci Adv. 2023 Aug 4;9(31):eadg2122. doi: 10.1126/sciadv.adg2122.
2
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
3
mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.mRNA 疫苗接种在未感染 SARS-CoV-2 的个体和既往感染 SARS-CoV-2 的个体中引发不同的黏膜中和抗体谱。
Front Immunol. 2022 Sep 8;13:953949. doi: 10.3389/fimmu.2022.953949. eCollection 2022.
4
Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.严重急性呼吸综合征冠状病毒 2 疫苗接种的黏膜和全身反应取决于初次感染的严重程度。
mSphere. 2022 Dec 21;7(6):e0027922. doi: 10.1128/msphere.00279-22. Epub 2022 Nov 2.
5
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后,人乳中能否检测到 SARS-CoV-2 抗体?
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.
6
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.第三剂 COVID-19 mRNA 疫苗接种后针对奥密克戎变异株的持续 T 细胞介导的免疫应答。
Front Immunol. 2023 Jan 23;14:1099246. doi: 10.3389/fimmu.2023.1099246. eCollection 2023.
7
Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.理解“混合免疫”:对严重急性呼吸综合征冠状病毒 2 感染(SARS-CoV-2)和 2019 年冠状病毒病(COVID-19)疫苗的体液免疫反应的比较和预测因素。
Clin Infect Dis. 2023 Feb 8;76(3):e439-e449. doi: 10.1093/cid/ciac392.
8
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.在 SARS-CoV-2 初免和既往感染人群中,BNT162b2 mRNA 疫苗对细胞和体液免疫应答的动力学和持久性:加强针和突破性感染的影响。
Front Immunol. 2022 May 31;13:863554. doi: 10.3389/fimmu.2022.863554. eCollection 2022.
9
Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.新型冠状病毒肺炎信使核糖核酸疫苗接种后的血清及唾液免疫球蛋白G和免疫球蛋白A反应
JAMA Netw Open. 2024 Apr 1;7(4):e248051. doi: 10.1001/jamanetworkopen.2024.8051.
10
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.评估 COVID-19 引起的全身和黏膜免疫反应以及 BNT162b2 mRNA 疫苗对 SARS-CoV-2 的作用。
PLoS One. 2022 Oct 18;17(10):e0263861. doi: 10.1371/journal.pone.0263861. eCollection 2022.

引用本文的文献

1
Longitudinal Immunoprofiling of the CD8 T-Cell Response in SARS-CoV-2 mRNA Vaccinees and COVID-19 Patients.新冠病毒mRNA疫苗接种者和新冠肺炎患者中CD8 T细胞反应的纵向免疫分析
Vaccines (Basel). 2025 May 22;13(6):551. doi: 10.3390/vaccines13060551.
2
NicOPURE: nickless RNA circularization and one-step purification with engineered group II introns and cyclizing UTRs.NicOPURE:利用工程化II组内含子和环化非翻译区实现无切口RNA环化及一步纯化
Nucleic Acids Res. 2025 Apr 10;53(7). doi: 10.1093/nar/gkaf310.

本文引用的文献

1
Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients.在 COVID-19 患者中,抗刺突体液免疫应答的数量和质量低与 CD4 T 细胞凋亡有关。
Cell Death Dis. 2022 Aug 27;13(8):741. doi: 10.1038/s41419-022-05190-0.
2
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.抗体和抗病毒药物对奥密克戎BA.2.12.1、BA.4和BA.5亚变体的疗效。
N Engl J Med. 2022 Aug 4;387(5):468-470. doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20.
3
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
SARS-CoV-2 奥密克戎亚变种 BA.2.12.1、BA.4 和 BA.5 的抗体逃逸
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
4
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.保护和衰减对 SARS-CoV-2 的天然和混合免疫。
N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946. Epub 2022 May 25.
5
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.分析记忆 B 细胞鉴定出变异 SARS-CoV-2 刺突蛋白 N 端结构域上的保守中和表位。
Immunity. 2022 Jun 14;55(6):998-1012.e8. doi: 10.1016/j.immuni.2022.04.003. Epub 2022 Apr 7.
6
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.印记的新冠病毒特异性记忆淋巴细胞定义了混合免疫。
Cell. 2022 Apr 28;185(9):1588-1601.e14. doi: 10.1016/j.cell.2022.03.018. Epub 2022 Mar 17.
7
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.在以色列,第四剂 BNT162b2 对奥密克戎的保护作用。
N Engl J Med. 2022 May 5;386(18):1712-1720. doi: 10.1056/NEJMoa2201570. Epub 2022 Apr 5.
8
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)自然获得性免疫与疫苗诱导免疫、再感染与突破感染:一项回顾性队列研究。
Clin Infect Dis. 2022 Aug 24;75(1):e545-e551. doi: 10.1093/cid/ciac262.
9
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.mRNA-1273 和 BNT162b2 COVID-19 疫苗诱导的抗体在 Fc 介导的效应功能方面存在差异。
Sci Transl Med. 2022 May 18;14(645):eabm2311. doi: 10.1126/scitranslmed.abm2311.
10
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.SARS-CoV-2 变体包括 B.1.1.529 等的强效抗体中和作用的结构基础。
Science. 2022 Apr 22;376(6591):eabn8897. doi: 10.1126/science.abn8897.